Title: Curative effect comparison of rHuEPO-β and rHuEPO-α in the treatment of renal anemia
Abstract: Objective To compare the curative effect and adverse reaction of recombinant hu-man erythropoietin beta(rHuEPO-β)and recombinant human erythropoietin alpha( rHuEPO-α)in the treatment of renal anemia. Methods Forty-nine patients unterwent maintenance hemodialysis and hemo-globin(Hb) 〈 90 g / L from February 2012 to May 2013 in people’s hospital of Shizhong district of Zaozhuang were chose as the object of study,and were divided into two groups randomly. Experimental group was given rHuEPO-β with subcutaneous injection and control group was given rHuEPO-α with sub-cutaneous injection respectively. The hemoglobin,hematocrit changes,the average time to achieve Hb targets value,the average dose of erythropoietin( EPO)using,and adverse reactions between the two groups before and after treatment was compared. Results Compared with before treatment,the levels of Hb in both groups increased significantly at 4 weeks after treatment(P 〈 0. 05);the levels of Hb in ex-perimental group were higher than that in control group at 4,8,12 weeks after treatment(P 〈 0. 05);af-ter 16 weeks of treatment,there was no significant difference in Hb levels between the two groups(P 〉0. 05). The average time to achieve Hb targets value and the average dose of erythropoietin(EPO)using in the experimental group were lower than those in the control group(P 〈 0. 05). The experimental group had less adverse reaction than that in the control group. Conclusions Subcutaneous injection of rHuE-PO-β and rHuEPO-α in treatment of renal anemia are effective,but rHuEPO-β has more rapid onset, less dosage,better compliance and less adverse reaction than rHuEPO-α in treatment of renal anemia.
Key words:
EPO- β ; rHuEPO- α; Renal anemiarHu
Publication Year: 2014
Publication Date: 2014-07-25
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot